Enhancement of myocardial and vascular function after phosphodiesterase-5 inhibition in a rat model

Sivakkanan Loganathan, T. Radovits, Sevil Korkmaz, Kristóf Hirschberg, Enikö Barnucz, Alexander Weymann, Timo Bömicke, Rawa Arif, Matthias Karck, G. Szabó

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Recent studies have shown the potential of PDE-5 inhibition on acute and chronic heart failure. Nevertheless it remained unclear, how far load-reducing properties and direct effects onmyocardial contractility are responsible for these observations. In the present study, we investigated the effects of vardenafil onmyocardial contractility and vascular function in a dose-response study. Methods: We performed left ventricular pressure-volume analysis in young adult rats by using a Millar microtip conductance catheter. Pressure-volume loops were recorded before and after intravenous injection of vardenafil (3, 10, 30, 100, 300 μg/kg, n = 6/group). Results: Treatment with vardenafil resulted in a significant (p <0.05) increase in the load-independent cardiac contractility parameters reaching its maximum at the dose of 100μg/kg (ESPVR: 2.15 ± 0.15 vs. 3.29 ± 0.26 mm Hg/μL; PRSW: 93.28 plusmn; 4.04 vs. 134.90 ± 6.27 mm Hg; peak positive dP/dt/EDV: 38.73 ± 7.97 vs. 53.02 ± 3.74 mm Hg·s -1·μL -1; before versus after 100 μg/kg vardenafil). Results of the in vitro organ-bath experiments showed an augmented vasorelaxation of precontracted aortic rings after vardenafil treatment. Conclusion: Our data supports the hypothesis that the usage of vardenafil as "inodilators" could have beneficial effects in heart failure patients.

Original languageEnglish
Pages (from-to)247-254
Number of pages8
JournalThoracic and Cardiovascular Surgeon
Volume60
Issue number4
DOIs
Publication statusPublished - 2012

Fingerprint

Type 5 Cyclic Nucleotide Phosphodiesterases
Blood Vessels
Heart Failure
Ventricular Pressure
Baths
Vasodilation
Intravenous Injections
Vardenafil Dihydrochloride
Young Adult
Catheters
Pressure
Therapeutics

Keywords

  • Cardiac function
  • Contractility
  • Heart failure
  • Pde-5 inhibition

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pulmonary and Respiratory Medicine

Cite this

Enhancement of myocardial and vascular function after phosphodiesterase-5 inhibition in a rat model. / Loganathan, Sivakkanan; Radovits, T.; Korkmaz, Sevil; Hirschberg, Kristóf; Barnucz, Enikö; Weymann, Alexander; Bömicke, Timo; Arif, Rawa; Karck, Matthias; Szabó, G.

In: Thoracic and Cardiovascular Surgeon, Vol. 60, No. 4, 2012, p. 247-254.

Research output: Contribution to journalArticle

Loganathan, S, Radovits, T, Korkmaz, S, Hirschberg, K, Barnucz, E, Weymann, A, Bömicke, T, Arif, R, Karck, M & Szabó, G 2012, 'Enhancement of myocardial and vascular function after phosphodiesterase-5 inhibition in a rat model', Thoracic and Cardiovascular Surgeon, vol. 60, no. 4, pp. 247-254. https://doi.org/10.1055/s-0031-1298059
Loganathan, Sivakkanan ; Radovits, T. ; Korkmaz, Sevil ; Hirschberg, Kristóf ; Barnucz, Enikö ; Weymann, Alexander ; Bömicke, Timo ; Arif, Rawa ; Karck, Matthias ; Szabó, G. / Enhancement of myocardial and vascular function after phosphodiesterase-5 inhibition in a rat model. In: Thoracic and Cardiovascular Surgeon. 2012 ; Vol. 60, No. 4. pp. 247-254.
@article{73a7f6b7102c46319c3afb0db7c5d352,
title = "Enhancement of myocardial and vascular function after phosphodiesterase-5 inhibition in a rat model",
abstract = "Background: Recent studies have shown the potential of PDE-5 inhibition on acute and chronic heart failure. Nevertheless it remained unclear, how far load-reducing properties and direct effects onmyocardial contractility are responsible for these observations. In the present study, we investigated the effects of vardenafil onmyocardial contractility and vascular function in a dose-response study. Methods: We performed left ventricular pressure-volume analysis in young adult rats by using a Millar microtip conductance catheter. Pressure-volume loops were recorded before and after intravenous injection of vardenafil (3, 10, 30, 100, 300 μg/kg, n = 6/group). Results: Treatment with vardenafil resulted in a significant (p <0.05) increase in the load-independent cardiac contractility parameters reaching its maximum at the dose of 100μg/kg (ESPVR: 2.15 ± 0.15 vs. 3.29 ± 0.26 mm Hg/μL; PRSW: 93.28 plusmn; 4.04 vs. 134.90 ± 6.27 mm Hg; peak positive dP/dt/EDV: 38.73 ± 7.97 vs. 53.02 ± 3.74 mm Hg·s -1·μL -1; before versus after 100 μg/kg vardenafil). Results of the in vitro organ-bath experiments showed an augmented vasorelaxation of precontracted aortic rings after vardenafil treatment. Conclusion: Our data supports the hypothesis that the usage of vardenafil as {"}inodilators{"} could have beneficial effects in heart failure patients.",
keywords = "Cardiac function, Contractility, Heart failure, Pde-5 inhibition",
author = "Sivakkanan Loganathan and T. Radovits and Sevil Korkmaz and Krist{\'o}f Hirschberg and Enik{\"o} Barnucz and Alexander Weymann and Timo B{\"o}micke and Rawa Arif and Matthias Karck and G. Szab{\'o}",
year = "2012",
doi = "10.1055/s-0031-1298059",
language = "English",
volume = "60",
pages = "247--254",
journal = "Thoracic and Cardiovascular Surgeon",
issn = "0171-6425",
publisher = "Georg Thieme Verlag",
number = "4",

}

TY - JOUR

T1 - Enhancement of myocardial and vascular function after phosphodiesterase-5 inhibition in a rat model

AU - Loganathan, Sivakkanan

AU - Radovits, T.

AU - Korkmaz, Sevil

AU - Hirschberg, Kristóf

AU - Barnucz, Enikö

AU - Weymann, Alexander

AU - Bömicke, Timo

AU - Arif, Rawa

AU - Karck, Matthias

AU - Szabó, G.

PY - 2012

Y1 - 2012

N2 - Background: Recent studies have shown the potential of PDE-5 inhibition on acute and chronic heart failure. Nevertheless it remained unclear, how far load-reducing properties and direct effects onmyocardial contractility are responsible for these observations. In the present study, we investigated the effects of vardenafil onmyocardial contractility and vascular function in a dose-response study. Methods: We performed left ventricular pressure-volume analysis in young adult rats by using a Millar microtip conductance catheter. Pressure-volume loops were recorded before and after intravenous injection of vardenafil (3, 10, 30, 100, 300 μg/kg, n = 6/group). Results: Treatment with vardenafil resulted in a significant (p <0.05) increase in the load-independent cardiac contractility parameters reaching its maximum at the dose of 100μg/kg (ESPVR: 2.15 ± 0.15 vs. 3.29 ± 0.26 mm Hg/μL; PRSW: 93.28 plusmn; 4.04 vs. 134.90 ± 6.27 mm Hg; peak positive dP/dt/EDV: 38.73 ± 7.97 vs. 53.02 ± 3.74 mm Hg·s -1·μL -1; before versus after 100 μg/kg vardenafil). Results of the in vitro organ-bath experiments showed an augmented vasorelaxation of precontracted aortic rings after vardenafil treatment. Conclusion: Our data supports the hypothesis that the usage of vardenafil as "inodilators" could have beneficial effects in heart failure patients.

AB - Background: Recent studies have shown the potential of PDE-5 inhibition on acute and chronic heart failure. Nevertheless it remained unclear, how far load-reducing properties and direct effects onmyocardial contractility are responsible for these observations. In the present study, we investigated the effects of vardenafil onmyocardial contractility and vascular function in a dose-response study. Methods: We performed left ventricular pressure-volume analysis in young adult rats by using a Millar microtip conductance catheter. Pressure-volume loops were recorded before and after intravenous injection of vardenafil (3, 10, 30, 100, 300 μg/kg, n = 6/group). Results: Treatment with vardenafil resulted in a significant (p <0.05) increase in the load-independent cardiac contractility parameters reaching its maximum at the dose of 100μg/kg (ESPVR: 2.15 ± 0.15 vs. 3.29 ± 0.26 mm Hg/μL; PRSW: 93.28 plusmn; 4.04 vs. 134.90 ± 6.27 mm Hg; peak positive dP/dt/EDV: 38.73 ± 7.97 vs. 53.02 ± 3.74 mm Hg·s -1·μL -1; before versus after 100 μg/kg vardenafil). Results of the in vitro organ-bath experiments showed an augmented vasorelaxation of precontracted aortic rings after vardenafil treatment. Conclusion: Our data supports the hypothesis that the usage of vardenafil as "inodilators" could have beneficial effects in heart failure patients.

KW - Cardiac function

KW - Contractility

KW - Heart failure

KW - Pde-5 inhibition

UR - http://www.scopus.com/inward/record.url?scp=84862282911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862282911&partnerID=8YFLogxK

U2 - 10.1055/s-0031-1298059

DO - 10.1055/s-0031-1298059

M3 - Article

C2 - 22252326

AN - SCOPUS:84862282911

VL - 60

SP - 247

EP - 254

JO - Thoracic and Cardiovascular Surgeon

JF - Thoracic and Cardiovascular Surgeon

SN - 0171-6425

IS - 4

ER -